A5002055690- Lung Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Advanced Radiotherapy Techniques
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Global Cancer Incidence and Screening
- Radiation Therapy and Dosimetry
- Occupational and environmental lung diseases
- Pleural and Pulmonary Diseases
- Radiomics and Machine Learning in Medical Imaging
- Head and Neck Cancer Studies
- Advances in Oncology and Radiotherapy
- Medical Imaging Techniques and Applications
- Epigenetics and DNA Methylation
- Colorectal Cancer Screening and Detection
- RNA modifications and cancer
- Radiation Dose and Imaging
- Neuroendocrine Tumor Research Advances
- Esophageal Cancer Research and Treatment
- Glioma Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Prostate Cancer Treatment and Research
- Pancreatic and Hepatic Oncology Research
- Gastric Cancer Management and Outcomes
- Management of metastatic bone disease
Peter MacCallum Cancer Centre
2020-2025
The University of Melbourne
2022-2025
Monash University
2021-2024
Addenbrooke's Hospital
2013-2022
Cambridge University Hospitals NHS Foundation Trust
2007-2021
Royal College of Physicians
2016-2020
National Cancer Registration Service
2019-2020
Bridge University
2019
University of Cambridge
2018-2019
Public Health England
2019
BackgroundConcurrent chemoradiotherapy is the standard of care in limited-stage small-cell lung cancer, but optimal radiotherapy schedule and dose remains controversial. The aim this study was to establish a treatment regimen cancer.MethodsThe CONVERT trial an open-label, phase 3, randomised superiority trial. We enrolled adult patients (aged ≥18 years) who had cytologically or histologically confirmed Eastern Cooperative Oncology Group performance status 0–2, adequate pulmonary function....
Identification of residual disease in patients with localized non-small cell lung cancer (NSCLC) following treatment curative intent holds promise to identify at risk relapse. New methods can detect circulating tumour DNA (ctDNA) plasma fractional concentrations as low a few parts per million, and clinical evidence is required inform their use.
### Spontaneous pneumothorax #### Acute management for spontaneous ##### Recommendations Good practice points Optimal after the resolution of a first episode and ongoing air leak point
IntroductionHepatotoxicity from T-cell checkpoint blockade is an increasingly common immune-related adverse event, but remains poorly characterised and can be challenging to manage. Such toxicity generally considered resemble autoimmune hepatitis, although this assumption extrapolated limited clinicopathological reports of anti-cytotoxic T-lymphocyte-associated protein 4-induced hepatotoxicity.MethodsHere we report, with full correlation, three cases inhibitor-induced hepatotoxicity...
Purpose Treating small-cell lung cancer (SCLC) remains a therapeutic challenge. Experimental studies show that statins exert additive effects with agents, such as cisplatin, to impair tumor growth, and observational suggest combined anticancer therapies delay relapse prolong life in several types. To our knowledge, we report the first large, randomized, placebo-controlled, double-blind trial of statin standard-of-care for patients cancer, specifically SCLC. Patients Methods confirmed SCLC...
No AccessJournal of UrologyINVESTIGATIVE UROLOGY1 Mar 2003Quantitative Gstp1 Methylation Clearly Distinguishes Benign Prostatic Tissue And Limited Prostate Adenocarcinoma SUSAN V. HARDEN, ZHONGMIN GUO, JONATHAN I. EPSTEIN, and DAVID SIDRANSKY HARDENSUSAN HARDEN , GUOZHONGMIN GUO EPSTEINJONATHAN EPSTEIN SIDRANSKYDAVID View All Author Informationhttps://doi.org/10.1097/01.ju.0000049627.90307.4dAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints...
Hypermethylation of the 5′ promoter region glutathione S-transferase π gene (GSTP1) occurs at a very high frequency in prostate adenocarcinoma. We compared results blinded histologic review sextant biopsy samples from 72 excised prostates with those obtained using quantitative methylation-specific polymerase chain reaction assay (QMSP) for GSTP1. Formal surgical pathologic resected was used to determine number patients (n = 61) and without 11) cancer. Histology alone detected carcinoma 64%...
<h3>Background</h3> Tumor-specific molecular alterations in surgical margins have been shown to predict risk of local recurrence. However, assays used for these analyses are time-consuming and therefore cannot be the intraoperative setting. <h3>Objective</h3> To detect quantify tumor-specific methylated promoter sequences a time frame suitable use. <h3>Design</h3> A novel quantitative methylation-specific polymerase chain reaction (QMSP) protocol. <h3>Methods</h3> total 13 patients with head...
Introduction Following growing evidence to support the safety, local control (LC) and potential improvement in overall survival (OS) patients with oligometastatic non-small cell lung cancer (NSCLC) that have been treated ablative therapy such as stereotactic radiotherapy (SABR) radiosurgery (SRS), we initiate SARON trial investigate impact feasibility of adding SABR/SRS radical (RRT) following standard chemotherapy on OS. Methods analysis is a large, randomised controlled, multicentre, phase...
Abstract Purpose: In this study, we tested the ability of a panel hypermethylation markers to improve sensitivity histologic prostate cancer detection in sextant needle biopsies. Experimental Design: We obtained fresh-frozen biopsies from 72 excised prostates and directly compared blinded review quantitative real-time methylation-specific PCR for four genes, Tazarotene-induced gene 1 (TIG1), adenomatous polyposis coli (APC), retinoic acid receptor β2 (RARβ2), glutathione S-transferase π...
To report toxicity and early survival data for IDEAL-CRT, a trial of dose-escalated concurrent chemoradiotherapy (CRT) non-small cell lung cancer.
Introduction Brain metastases commonly occur in patients with non-small cell lung cancer (NSCLC). Standard first-line treatment for NSCLC, without an EGFR, ALK or ROS1 mutation, is either chemoimmunotherapy anti-PD-1 monotherapy. Traditionally, symptomatic untreated brain were excluded from the pivotal clinical trials that established recommendations. The intracranial effectiveness of these protocols has only recently been elucidated small-scale prospective trials. Methods Patients NSCLC and...